Supplementary Figure S1 from CAR T-cell Kinetics, Persistence, and Clinical Outcomes in Adult Patients with Relapsed/Refractory B-cell ALL Treated with Obecabtagene Autoleucel in the FELIX Study

Authors:
Open Access
Publisher website
Google Scholar
Abstract
Kaplan-Meier landmark analysis of EFS among patients with ongoing remission without new anti-cancer therapies, by CAR T-cell persistence by intracellular flow cytometry at A) Month 3 and B) Month 6.